You seem to know a lot about the company. How is it that the product seems to be in use overseas and could fail here. Do you know if the results from Europe have been published as far as actual uses on patients and how they have fared. Liver cancer is a death sentence and I would travel anywhere on the planet(except Detroit or Cleveland) to have the catheter procedure done if I contracted the disease.
I know MAXM is having its way with shareholders, and though I cannot explain why management remains prostrate on the sideline, it does bear repeating that fundamentally, nothing about Delcath's drug portfolio--other than being featured in an upcoming peer-reviewed medical journal--has changed since this article was written.
Delcath Systems Offers Significant Upside For Risk-Tolerant Investors
Delcath Systems is developing unique, proprietary medical products which are aimed at treating the unmet needs of patients with liver cancer.
There has been significant regulatory and commercial progress in Europe as well as substantial clinical trial progress in the United States.
Recently released clinical data has provided shareholders with renewed optimism.
Financial difficulties must be addressed in the immediate future if Delcath Systems is to succeed.
Significant potential upside awaits investors who are willing to tolerate the risk associated with this investment.
Delcath Systems (DCTH) offers tremendous potential upside for investors who are willing to tolerate a high degree of risk. Shareholders stand to reap a financial windfall if the company manages to successfully navigate clinical, regulatory, and financial hurdles. Delcath Systems' rock-bottom share price provides investors with the opportunity to initiate a large position in the company and take advantage of this uniquely asymmetric risk/reward opportunity.
Many have felt the wrath of the asymmetric risk to be sure, but not the possibility of the asymmetric ascent.
News 
Market Data 
Discover 
